AbbVieABBV
About: AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Employees: 50,000
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
38% more first-time investments, than exits
New positions opened: 233 | Existing positions closed: 169
27% more call options, than puts
Call options by funds: $3.65B | Put options by funds: $2.87B
18% more funds holding in top 10
Funds holding in top 10: 174 [Q2] → 205 (+31) [Q3]
9% more capital invested
Capital invested by funds: $225B [Q2] → $245B (+$20.7B) [Q3]
2% more funds holding
Funds holding: 3,290 [Q2] → 3,354 (+64) [Q3]
1% more repeat investments, than reductions
Existing positions increased: 1,356 | Existing positions reduced: 1,345
3.5% less ownership
Funds ownership: 73.78% [Q2] → 70.28% (-3.5%) [Q3]
Research analyst outlook
18 Wall Street Analysts provided 1 year price targets over the past 3 months
18 analyst ratings
Wolfe Research Alexandria Hammond 0% 1-year accuracy 0 / 1 met price target | 24%upside $205 | Outperform Initiated | 15 Nov 2024 |
JP Morgan Chris Schott 29% 1-year accuracy 5 / 17 met price target | 21%upside $200 | Overweight Maintained | 13 Nov 2024 |
Citigroup Geoff Meacham 42% 1-year accuracy 10 / 24 met price target | 30%upside $215 | Buy Maintained | 12 Nov 2024 |
BMO Capital Evan David Seigerman 18% 1-year accuracy 3 / 17 met price target | 26%upside $208 | Outperform Maintained | 12 Nov 2024 |
Morgan Stanley Terence Flynn 31% 1-year accuracy 5 / 16 met price target | 36%upside $224 | Overweight Maintained | 12 Nov 2024 |
Financial journalist opinion
Based on 71 articles about ABBV published over the past 30 days
